What does this mean for MA holders?
- The issuance of marketing authorisations in MRP/DCP and for parallel-imported medicinal products is affected by the temporary delays.
- Cases in the centralised procedure are currently being handled largely within the applicable deadlines.
- Safety updates are prioritised and processed on an ongoing basis.
The delays are expected to continue into 2026. It is currently uncertain when the situation will be fully normalised, but we are monitoring developments closely and will publish updated information as needed.
See the previous news article on the new case-processing platform.